DLX5 and non-small cell lung carcinoma: Previous studies have reported that DLX5 is upregulated in human lymphomas and non-small cell lung cancer, where it could bind to the MYC promoter to activate its transcription (Xu and Testa, 2009; Sun et al., 2020).